439PD - Peptide receptor radionuclide therapy of neuroendocrine neoplasms using Lutetium-177 and Yttrium-90 labeled somatostatin analogs - a single center...

Date 11 September 2017
Event ESMO 2017 Congress
Session Endocrine and neuroendocrine tumours
Topics Neuroendocrine Cancers
Endocrine Cancers
Presenter Aviral Singh
Citation Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368
Authors A. Singh1, H.R. Kulkarni1, T. Langbein1, C. Lehmann1, K. Niepsch1, D. Müller1, M. Hommann2, D. Kaemmerer2, A. Jochems3, P. Lambin4, D. Hörsch5, R.P. Baum1
  • 1Theranostics Center For Molecular Radionuclide Therapy And Molecular Imaging, Zentralklinik Bad Berka GmbH, 99437 - Bad Berka/DE
  • 2Department Of General And Visceral Surgery, Zentralklinik Bad Berka GmbH, 99437 - Bad Berka/DE
  • 3Department Of Radiation Oncology, MAASTRO Clinic, Maastricht/NL
  • 4Grow - School For Oncology And Developmental Biology, Maastricht University, 6229 - Maastricht/NL
  • 5Department Of Internal Medicine, Zentralklinik Bad Berka GmbH, 99437 - Bad Berka/DE



Peptide receptor radionuclide therapy (PRRT) of patients with somatostatin receptor expressing gastroenteropancreatic neuroendcrine neoplasms (NEN) has shown promising results in a recently published clinical trial (NETTER-1, NEJM, Jan 2017). In this study, we performed an intention to treat analysis in over 1000 patients with NEN (pancreas, mid-gut, lung and others) treated at our center.


From 2004, 1048 patients received at least one cycle of Yttrium-90 or Lutetium-177 based PRRT, and were included in an intention to treat analysis. Ga-68 somatostatin receptor (SSR) PET/CT was used for restaging and response to therapy assessment (EORTC criteria). Accordingly, overall survival (OS) and progression free survival (PFS) were calculated. Adverse events (hematotoxicity and nephrotoxicity) were determined by CTCAE (v4.03).


Overall survival (95% CI) was 51 months (47.0-54.9) and differed according to tumor grade, location of primary tumor, functionality, previous therapies, and the radioisotope used for PRRT. PFS was 19 months (16.9-21.0), which was influenced by tumor grade, location of primary tumor, and the radioisotope used for PRRT. PFS after initial progression and first and second resumption of PRRT, following therapy-free intervals of > 6 months, was 11 months (9.4-12.5) and 8 months (6.4-9.5), respectively. Myelodysplastic syndrome or leukemia developed in 2.1% patients. No grade 4 nephrotoxicity was observed with Lu-177. Few patients with severe renal dysfunction before PRRT, progressed to end-stage renal disease. No patient with normal renal function before PRRT developed G3 (or higher) nephrotoxicity.


PRRT is effective as it favorably prolongs the OS and PFS in patients with metastatic neuroendocrine neoplasms. However, this depends on the tumor grade, location of primary tumor, and the radionuclide used for therapy. Low rate of severe hematotoxicity were observed. There was no therapy associated severe nephrotoxicity in patients with normal renal function prior to commencement of PRRT.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Richard P. Baum




All authors have declared no conflicts of interest.